Efficacy and safety of inclisiran versus PCSK9 inhibitor versus statin plus ezetimibe therapy in hyperlipidemia: a systematic review and network meta-analysis.

BMC Cardiovasc Disord · 2024 · PMC11549808 · PMID 39521985

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

The SUCRA probability indicated a degree of superiority for inclisiran; however, this advantage did not reach statistical significance when comparing the combination of statin and ezetimibe therapy with PCSK9 inhibitors.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.